Autologous Stem Cell Transplantation for Crohn's Disease
Phase 1/2
20
about 16 years
10–60
2 sites in PA
What this study is about
This trial is testing the safety and effectiveness of a treatment using autologous CD34-selected peripheral blood stem cells in adults and children with severe Crohn's disease. The treatment involves high-dose chemotherapy followed by stem cell infusion.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive autologous CD34-selected peripheral blood stem cells transplant
- 2.Take ATG
- 3.Take Alemtuzumab
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
alemtuzumab, cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), colony stimulating factor, melphalan, mesna, rituximab (Monoclonal antibody; targets CD20 on B-cells to destroy them), thiotepa
injection (Injection), infusion, injection, intravenous, oral (Oral Tablet)
Secondary: Biomarker identification for relapse
Gastroenterology